Escitalopram prevents relapse of obsessive-compulsive disorder

European Neuropsychopharmacology

Volumn 17, Issue 6-7, 2007, Pages 430-439

  Fineberg, Naomi A ^a   Tonnoir, Brigitte ^b   Lemming, Ole ^b   Stein, Dan J ^c  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^b H LUNDBECK A S   (Denmark)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Escitalopram; Obsessive compulsive disorder; OCD; Relapse prevention; Y BOCS; Yale Brown Obsessive Compulsive Scale

Indexed keywords

ESCITALOPRAM; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; LIBIDO DISORDER; LONG TERM CARE; MALE; MULTICENTER STUDY; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RHINOPHARYNGITIS; RISK ASSESSMENT; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; CITALOPRAM; DOUBLE-BLIND METHOD; HUMANS; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PATIENT SELECTION; PLACEBOS; RANDOM ALLOCATION; RECURRENCE; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 33947664975     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2006.11.005     Document Type: Article

References (34)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Text Revision (DSM-IV-TR). Fourth Edition (1994), American Psychiatric Publishing Inc., USA
2. Bailer D.C., Burnham D., and Oakes R. Long-term treatment with paroxetine of outpatients with obsessive-compulsive disorder; an extension of the companion study (2005). http://ctr.gsk.co.uk/Summary/paroxetine/studylist.asp http://ctr.gsk.co.uk/Summary/paroxetine/studylist.asp [study no.:MY-1053/BRL-029060/CPMS-127. Last accessed 22 November, 2006.
3. Baldwin, D.S., Montgomery, S.A., Nil, R., Lader, M., in press. Discontinuation symptoms in depression and anxiety disorders. Int. J. Neuropsychopharmacol. doi:10.1017/S1461145705006358.
4. Cottraux J., Note I., Yao S.N., Lafont S., Note B., Mollard E., Bouvard M., Sauteraud A., Bourgeois M., and Dartigues J.F. A randomized controlled trial of cognitive therapy versus intensive behavior therapy in obsessive compulsive disorder. Psychother. Psychosom. 70 (2001) 288-297
5. Eddy K.T., Dutra L., Bradley R., and Westen D. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin. Psychol. Rev. 24 (2004) 1011-1030
6. Fineberg N.A., and Gale T.M. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int. J. Neuropsychopharmacol. 8 (2005) 107-129
7. Geller D.A., Biederman J., Stewart S.E., Mullin B., Farrell C., Wagner K.D., Emslie G., and Carpenter D. Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?. J. Child Adolesc. Psychopharmacol. 13 Suppl. 1 (2003) S19-S29
8. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischmann R.L., Hill C.L., Heninger G.R., and Charney D.S. The Yale-Brown Obsessive Compulsive Scale. I, Development, use, and reliability. Arch. Gen. Psychiatry 46 (1989) 1006-1011
9. Greist J.H., Jefferson J.W., Kobak K.A., Chouinard G., DuBoff E., Halaris A., Kim S.W., Koran L., Liebowtiz M.R., Lydiard B., et al. A one year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int. Clin. Psychopharmacol. 10 (1995) 57-65
10. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised. US Dept Health, Education, and Welfare publication (ADM) (1976), National Institute of Mental Health, Rockville, MD 76-338
11. Hollander E., Koran L.M., Goodman W.K., Greist J.H., Ninan P.T., Yang H., Li D., and Barbato L.M. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J. Clin. Psychiatry 64 (2003) 640-647
12. Hollander E., Allen A., Steiner M., Wheadon D.E., Oakes R., Burnham L.M., and Paroxetine OCD Study Group. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J. Clin. Psychiatry 64 (2003) 1113-1121
13. ICH. ICH Harmonised Tripartite Guideline E6: Guideline for Good Clinical Practice (1996). http://www.emea.eu.int/pdfs/human/ich/013595en.pdf%23search%3D%2522ich%2520e6%2522 Available from: http://www.emea.eu.int/pdfs/human/ich/013595en.pdf#search=%22ich%20e6%22. Last accessed 5 October, 2006.
14. Insel T.R., Murphy D.L., Cohen R.M., Alterman I., Kilts C., and Linnoila M. Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline. Arch. Gen. Psychiatry 40 (1983) 605-612
15. Katz R.J., DeVeaugh-Geiss J., and Landau P. Clomipramine in obsessive-compulsive disorder. Biol. Psychiatry 28 (1990) 401-414
16. Kessler R.C., Berglund P., Demler O., Jin R., Merikangas K.R., and Walters E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62 (2005) 593-602
17. Kessler R.C., Chiu W.T., Demler O., Merikangas K.R., and Walters E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 62 (2005) 617-627
18. Koran L.M., Hackett E., Rubin A., Wolkow R., and Robinson D. Efficacy of sertraline in the long-term treatment of obsessive compulsive disorder. Am. J. Psychiatry 159 (2002) 88-95
19. Maina G., Albert U., and Bogetto F. Relapses after discontinuation of drug associated with increased resistance to treatment in obsessive-compulsive disorder. Int. Clin. Psychopharmacol. 16 (2001) 33-38
20. McLean P.D., Whittal M.L., Thordarson D.S., Taylor S., Sochting I., Koch W.J., Paterson R., and Anderson K.W. Cognitive versus behavior therapy in the group treatment of obsessive-compulsive disorder. J. Consult. Clin. Psychol. 69 (2001) 205-214
21. Montgomery S.A., and Åsberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134 (1979) 382-389
22. Montgomery S.A., Kasper S., Stein D.J., Hedegaard K.B., and Lemming O.M. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int. Clin. Psychopharmacol. 16 (2001) 75-86
23. Pato M.T., Zohar-Kadouch R., Zohar J., and Murphy D.L. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am. J. Psychiatry 145 (1988) 1521-1525
24. Robins L.N., Helzer J.E., Weissman M.M., Orvaschel H., Gruenberg E., Burke Jr. J.D., and Regier D.A. Lifetime prevalence of specific psychiatric disorders in three sites. Arch. Gen. Psychiatry 41 (1984) 949-958
25. Romano S., Goodman W., Tamura R., and Gonzales J. Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J. Clin. Psychopharmacol. 21 (2001) 46-52
26. Sanchez C., Bogeso K.P., Ebert B., Reines E.H., and Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology 174 (2004) 163-176
27. Simpson H.B., Franklin M.E., Cheng J., Foa E.B., and Liebowitz M.R. Standard criteria for relapse are needed in obsessive-compulsive disorder. Depress. Anxiety 21 (2005) 1-8
28. Simpson H.B., Huppert J.D., Petkova E., Foa E.B., and Liebowitz M.R. Response versus remission in obsessive-compulsive disorder. J. Clin. Psychiatry 67 (2006) 269-276
29. Skoog G., and Skoog I. A 40-year follow up of patients with obsessive-compulsive disorder. Arch. Gen. Psychiatry 56 (1999) 121-127
30. Stein D.J., Tonnoir B., and Andersen E.W. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine referenced, fixed dose, 24-week study. Poster presented at the American Psychiatric Association Annual Meeting (2006) Toronto, Canada (2006)
31. Tollefson G.D., Birkett M., Koran L., and Genduso L. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. J. Clin. Psychiatry 55 (1994) 69-76 (Suppl.)
32. van Oppen P., de Haan E., van Balkom A.J., Spinhoven P., Hoogduin K., and van Dyck R. Cognitive therapy and exposure in vivo in the treatment of obsessive compulsive disorder. Behav. Res. Ther. 33 (1995) 379-390
33. Weissman M.M., Bland R.C., Canino G.J., Greenwald S., Hwu H.G., Lee C.K., Newman S.C., Oakley-Browne M.A., Rubio-Stipec M., Wickramaratne P.J., et al. The cross national epidemiology of obsessive compulsive disorder. J. Clin. Psychiatry 55 Suppl. (1994) 5-10
34. World Medical Association (WMA). Declaration of Helsinki: ethical principles for medical research involving human subjects (1964). http://www.wma.net/e/ethicsunit/helsinki.htm Available from: http://www.wma.net/e/ethicsunit/helsinki.htm. Last accessed 5 October, 2006